Literature DB >> 25262443

Mortality in schizophrenia and other psychoses: a 10-year follow-up of the ӔSOP first-episode cohort.

Ulrich Reininghaus1, Rina Dutta2, Paola Dazzan3, Gillian A Doody4, Paul Fearon5, Julia Lappin6, Margaret Heslin7, Adanna Onyejiaka8, Kim Donoghue9, Ben Lomas4, James B Kirkbride10, Robin M Murray3, Tim Croudace11, Craig Morgan12, Peter B Jones13.   

Abstract

The excess mortality in people with psychotic disorders is a major public health concern, but little is known about the clinical and social risk factors which may predict this health inequality and help inform preventative strategies. We aimed to investigate mortality in a large epidemiologically characterized cohort of individuals with first-episode psychosis compared with the general population and to determine clinical and social risk factors for premature death. All 557 individuals with first-episode psychosis initially identified in 2 areas (Southeast London and Nottinghamshire, United Kingdom) were traced over a 10-year period in the ӔSOP-10 study. Compared with the general population, all-cause (standardized mortality ratio [SMR] 3.6, 95% confidence interval [CI] 2.6-4.9), natural-cause (SMR 1.7, 95% CI 1.0-2.7) and unnatural-cause (SMR 13.3, 95% CI 8.7-20.4) mortality was very high. Illicit drug use was associated with an increased risk of all-cause mortality (adj. rate ratio [RR] 2.31, 95% CI 1.06-5.03). Risk of natural-cause mortality increased with a longer time to first remission (adj. RR 6.61, 95% CI 1.33-32.77). Family involvement at first contact strongly reduced risk of unnatural-cause mortality (adj. RR 0.09, 95% CI 0.01-0.69). Our findings suggest that the mortality gap in people with psychotic disorders remains huge and may be wider for unnatural-cause mortality than previously reported. Efforts should now focus on further understanding and targeting these tractable clinical and social risk factors of excess mortality. Early intervention and dual diagnosis services may play a key role in achieving more rapid remission and carer involvement and addressing substance use problems to reduce excess mortality in psychosis.
© The Author 2014. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.

Entities:  

Keywords:  mortality/; psychosis/; risk factors; schizophrenia/

Mesh:

Year:  2014        PMID: 25262443      PMCID: PMC4393685          DOI: 10.1093/schbul/sbu138

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  47 in total

1.  Incidence of hospitalised schizophrenia in Finland since 1980: decreasing and increasing again.

Authors:  Raimo K R Salokangas; Mika Helminen; Anna-Maija Koivisto; Helena Rantanen; Hannu Oja; Sami Pirkola; Kristian Wahlbeck; Matti Joukamaa
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-03-20       Impact factor: 4.328

Review 2.  Antipsychotic-induced weight gain: a comprehensive research synthesis.

Authors:  D B Allison; J L Mentore; M Heo; L P Chandler; J C Cappelleri; M C Infante; P J Weiden
Journal:  Am J Psychiatry       Date:  1999-11       Impact factor: 18.112

3.  Excess mortality of schizophrenia. A meta-analysis.

Authors:  S Brown
Journal:  Br J Psychiatry       Date:  1997-12       Impact factor: 9.319

4.  Mortality in chronic schizophrenia during decreasing number of psychiatric beds in Finland.

Authors:  Raimo K R Salokangas; Teija Honkonen; Eija Stengård; Anna-Maija Koivisto
Journal:  Schizophr Res       Date:  2002-04-01       Impact factor: 4.939

5.  Suicide prevention in first episode psychosis: the development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis.

Authors:  P J R Power; R J Bell; R Mills; T Herrman-Doig; M Davern; L Henry; H P Yuen; A Khademy-Deljo; P D McGorry
Journal:  Aust N Z J Psychiatry       Date:  2003-08       Impact factor: 5.744

Review 6.  Physical health monitoring of patients with schizophrenia.

Authors:  Stephen R Marder; Susan M Essock; Alexander L Miller; Robert W Buchanan; Daniel E Casey; John M Davis; John M Kane; Jeffrey A Lieberman; Nina R Schooler; Nancy Covell; Scott Stroup; Ellen M Weissman; Donna A Wirshing; Catherine S Hall; Leonard Pogach; Xavier Pi-Sunyer; J Thomas Bigger; Alan Friedman; David Kleinberg; Steven J Yevich; Bonnie Davis; Steven Shon
Journal:  Am J Psychiatry       Date:  2004-08       Impact factor: 18.112

7.  Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study.

Authors:  C Morgan; J Lappin; M Heslin; K Donoghue; B Lomas; U Reininghaus; A Onyejiaka; T Croudace; P B Jones; R M Murray; P Fearon; G A Doody; P Dazzan
Journal:  Psychol Med       Date:  2014-02-26       Impact factor: 7.723

8.  Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006.

Authors:  Uy Hoang; Robert Stewart; Michael J Goldacre
Journal:  BMJ       Date:  2011-09-13

9.  Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?

Authors:  Gary Remington
Journal:  Am J Psychiatry       Date:  2006-07       Impact factor: 19.242

10.  The reversal of fortunes: trends in county mortality and cross-county mortality disparities in the United States.

Authors:  Majid Ezzati; Ari B Friedman; Sandeep C Kulkarni; Christopher J L Murray
Journal:  PLoS Med       Date:  2008-04-22       Impact factor: 11.069

View more
  40 in total

1.  Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study.

Authors:  Saeko Ikai; Takefumi Suzuki; Masaru Mimura; Hiroyuki Uchida
Journal:  Psychopharmacology (Berl)       Date:  2016-09-08       Impact factor: 4.530

Review 2.  Mortality Risk Associated With Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled Trials.

Authors:  Taro Kishi; Shinji Matsunaga; Nakao Iwata
Journal:  Schizophr Bull       Date:  2016-04-16       Impact factor: 9.306

3.  A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.

Authors:  Taiwo Babatope; Jigar Chotalia; Rania Elkhatib; Satyajit Mohite; Joel Shah; Sumana Goddu; Ruchir Arvind Patel; Osarhiemen Ruth Aimienwanu; Devanshu Patel; Titilayo Makanjuola; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2016-12

4.  The iHOPE-20 study: mortality in first episode psychosis-a 20-year follow-up of the Dublin first episode cohort.

Authors:  Roisin Doyle; Donal O'Keeffe; Ailish Hannigan; Anthony Kinsella; Caragh Behan; Aine Kelly; Ann Sheridan; Kevin Madigan; Elizabeth Lawlor; Mary Clarke
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-05-09       Impact factor: 4.328

5.  Lifetime Prevalence and Correlates of Schizophrenia-Spectrum, Affective, and Other Non-affective Psychotic Disorders in the Chinese Adult Population.

Authors:  Wing Chung Chang; Corine Sau Man Wong; Eric Yu Hai Chen; Linda Chiu Wa Lam; Wai Chi Chan; Roger Man Kin Ng; Se Fong Hung; Eric Fuk Chi Cheung; Pak Chung Sham; Helen Fung Kum Chiu; Ming Lam; Edwin Ho Ming Lee; Tin Po Chiang; Lap Kei Chan; Gary Kar Wai Lau; Allen Ting Chun Lee; Grace Tak Yu Leung; Joey Shuk Yan Leung; Joseph Tak Fai Lau; Jim van Os; Glyn Lewis; Paul Bebbington
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

6.  Association between the hypertriglyceridemic waist phenotype and hyperuricemia: a cross-sectional study.

Authors:  Shuang Chen; Xiaofan Guo; Siyuan Dong; Shasha Yu; Yintao Chen; Naijin Zhang; Yingxian Sun
Journal:  Clin Rheumatol       Date:  2017-02-09       Impact factor: 2.980

7.  Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis.

Authors:  Davy Vancampfort; Brendon Stubbs; Alex J Mitchell; Marc De Hert; Martien Wampers; Philip B Ward; Simon Rosenbaum; Christoph U Correll
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

8.  Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis.

Authors:  Davy Vancampfort; Christoph U Correll; Britta Galling; Michel Probst; Marc De Hert; Philip B Ward; Simon Rosenbaum; Fiona Gaughran; John Lally; Brendon Stubbs
Journal:  World Psychiatry       Date:  2016-06       Impact factor: 49.548

Review 9.  Cardiorespiratory Fitness in Severe Mental Illness: A Systematic Review and Meta-analysis.

Authors:  Davy Vancampfort; Simon Rosenbaum; Felipe Schuch; Philip B Ward; Justin Richards; James Mugisha; Michel Probst; Brendon Stubbs
Journal:  Sports Med       Date:  2017-02       Impact factor: 11.136

10.  Association of an Early Intervention Service for Psychosis With Suicide Rate Among Patients With First-Episode Schizophrenia-Spectrum Disorders.

Authors:  Sherry Kit Wa Chan; Stephanie Wing Yan Chan; Herbert H Pang; Kang K Yan; Christy Lai Ming Hui; Wing Chung Chang; Edwin Ho Ming Lee; Eric Yu Hai Chen
Journal:  JAMA Psychiatry       Date:  2018-05-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.